Global Wound Biologics Market 2021

January 2022 | 20 pages | ID: GEEB794EEB18EN
StrategyHelix Inc

Abstracts

The global wound biologics market is poised to grow by US$ 2,042 million from 2021 to 2027, registering a CAGR of 11.5% during the forecast period, according to StrategyHelix. Rise in adoption of evidence-based treatments for chronic wounds, rapid increase in geriatric population, rise in disposable income in developing economies, rise in awareness toward advanced wound care treatment & management are expected to boost the market growth in the coming years.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for wound biologics. The global wound biologics market is segmented on the basis of product, wound type, end user, and region. By product, the global wound biologics market has been segmented into skin substitutes (CTPs), others. In 2020, the skin substitutes (CTPs) segment made up the largest share of revenue generated by the wound biologics market. Based upon wound type, the global wound biologics market is categorized into acute wounds, chronic wounds. On the basis of end user, the global wound biologics market has been segmented into hospitals, clinics. The hospitals segment is estimated to account for the largest share of the global wound biologics market. In terms of geography, the global wound biologics market has been segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global wound biologics market is highly competitive. The competitive landscape of the industry has also been examined along with the profiles of the key players Allergan plc (AbbVie Inc.), Amniox Medical Inc., Cook Biotech Inc., Integra LifeSciences Holdings Corporation, MiMedx Group Inc., MISONIX Inc., Organogenesis Holdings Inc., SANUWAVE Inc., Smith & Nephew plc, Vericel Corporation, Wright Medical Group N.V. (Stryker Corporation).

Report Scope
Product: skin substitutes (CTPs), others
Wound type: acute wounds, chronic wounds
End user: hospitals, clinics
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the global wound biologics market
Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. WOUND BIOLOGICS MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY PRODUCT

Skin substitutes (CTPs)
Others

PART 4. MARKET BREAKDOWN BY WOUND TYPE

Acute wounds
Chronic wounds

PART 5. MARKET BREAKDOWN BY END USER

Hospitals
Clinics

PART 6. MARKET BREAKDOWN BY REGION

North America
Asia Pacific
Europe
Rest of the World (ROW)

PART 7. KEY COMPANIES

Allergan plc (AbbVie Inc.)
Amniox Medical, Inc.
Cook Biotech Inc.
Integra LifeSciences Holdings Corporation
MiMedx Group, Inc.
MISONIX, Inc.
Organogenesis Holdings Inc.
SANUWAVE, Inc.
Smith & Nephew plc
Vericel Corporation
Wright Medical Group N.V. (Stryker Corporation)
About StrategyHelix
Disclaimer